Reference number : 236-2011-2012-Q4-00023, amendment number : , agreement type : G, recipient legal name : PRICA, Anca, recipient country : CA, recipient province : ON, recipient city : Toronto, recipient postal code : M4N 3M5, program name english : nan, program name french : nan, program purpose english : nan, program purpose french : nan, agreement title english : nan, agreement title french : nan, agreement number : nan, agreement value : 52917.0, agreement start date : 2012-05-01, agreement end date : 2013-04-30, description english : Phase II trial of Azacitidine plus Deferasirox in higher risk Myelodysplastic Syndromes (MDS), description french : Phase II trial of Azacitidine plus Deferasirox in higher risk Myelodysplastic Syndromes (MDS), expected results english : nan, expected results french : nan, additional information english : Grant or Award spanning more than one fiscal year.
(2012-13 to 2013-14)

Start date may be subject to change.  Funding for awards must commence within 12 months of the date of offer., additional information french : Subvention ou bourse octroyée s'appliquant à plus d'un exercice financier.
(2012-13 à 2013-14)

La date de début peut être sujet au changement.  Le financement des bourses doit commencer dans les 12 mois suivant la date à laquelle elles ont été offertes., owner organization : cihr-irsc, owner organization title : Canadian Institutes of Health Research | Instituts de recherche en santé du Canada